N-(3,5-dichloro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea | 810678-92-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,5-dichloro-phenyl)-N'-[3-(1H-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea
• 英文别名: 1-(3,5-dichlorophenyl)-3-[2-(2H-tetrazol-5-yl)-4-[3-(trifluoromethyl)phenyl]phenyl]urea
• CAS: 810678-92-3
• 化学式: C₂₁H₁₃Cl₂F₃N₆O
• 分子量: 493.275
• InChiKey: JVWZQRDKIMSXFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  95.6
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Diphenylurea derivatives and their use as chloride channel blockers
  申请人：Dahl H. Bjarne

  公开号：US20060178413A1

  公开（公告）日：2006-08-10

  The present invention relates to novel diphenylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, and to pharmaceutical compositions comprising the compounds of the invention.

  本发明涉及一种新型二苯基脲衍生物，其作为氯离子通道阻滞剂具有应用价值。在其他方面，本发明涉及这些化合物在治疗方法中的使用，以及包含本发明化合物的制药组合物。
• Diphenylurea Derivatives Useful As Potassium Channel Activators
  申请人：Dahl H. Bjarne

  公开号：US20070293553A1

  公开（公告）日：2007-12-20

  The present invention relates to the medical use of a certain group of diphenyl urea derivatives as potassium channel blockers for treating cardiovascular diseases, an obstructive or inflammatory airway disease, urinary incontinence, psychosis, epilepsy or pain, or for facilitating the blood-brain barrier permeability for other therapeutic substances. In other aspects the invention relates to the use of these compounds in a method of therapy.

  本发明涉及使用某些二苯基脲衍生物作为钾通道阻滞剂，用于治疗心血管疾病、阻塞性或炎性气道疾病、尿失禁、精神病、癫痫或疼痛，或用于促进其他治疗物质通过血脑屏障的渗透。在其他方面，本发明涉及这些化合物在治疗方法中的使用。
• DIPHENYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
  申请人：NEUROSEARCH A/S

  公开号：EP1638948B1

  公开（公告）日：2008-10-15
• BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER
  申请人：Canbex Therapeutics Limited

  公开号：US20180021303A1

  公开（公告）日：2018-01-25

  The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.
• US7691891B2
  申请人：——

  公开号：US7691891B2

  公开（公告）日：2010-04-06